Nastech Partners With Merck On Phase I Obesity Drug
This article was originally published in The Pink Sheet Daily
Nastech cites Merck’s demonstrated urgency to enter the class and its R&D capabilities as a reason to collaborate on the nasal spray agent earlier than planned and before it has completed Phase II trials. Merck would be primarily responsible for worldwide research, regulatory approvals, sales and marketing.
You may also be interested in...
Merck terminated a partnership March 1 to jointly develop Nastech's Phase I peptide YY3-36 nasal spray for treatment of obesity after concluding from a preliminary proof of concept study that it did not demonstrate efficacy
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.